Vanguard Portfolio Management
ESPR

Vanguard Portfolio Management’s Esperion Therapeutics ESPR Stock Holding History

Vanguard Portfolio Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.81M Sell
2,471,671
-1,060,892
-30% -$2.97M ﹤0.01% 2279
2026
Q1 		$9.68M Buy
+3,532,563
New +$11.2M ﹤0.01% 2124

Other funds holding ESPR

GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.16B AUM 43.32% 1-Year Est. Return

Vanguard Portfolio Management's ESPR Position: Q2 2026 in Review

Vanguard Portfolio Management reduced its Esperion Therapeutics (ESPR) stake by 30% in Q2 2026, selling an estimated $2.97M and leaving 2,471,671 shares worth $7.81M. The position accounts for ﹤0.01% of the portfolio, ranked #2279.

Vanguard Portfolio Management first reported a position in ESPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $9.68M in Q1 2026. 191 funds tracked by Wall St. Rank hold ESPR as of Q2 2026.

  • Vanguard Portfolio Management held 2,471,671 shares of Esperion Therapeutics worth $7.81M as of Q2 2026.
  • Vanguard Portfolio Management sold 1,060,892 Esperion Therapeutics shares in Q2 2026, an estimated $2.97M.
  • Esperion Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2279 holding.
  • Vanguard Portfolio Management first reported a position in Esperion Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Portfolio Management's Esperion Therapeutics position peaked at $9.68M in Q1 2026.
  • 191 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.